Will third time be the charm? Lexicon finally refiles SGLT2 drug for heart failure

Lexicon’s experimental treatment of heart failure is finally on its way to the FDA — again.

The Woodlands, TX-based biotech says it’s resubmitted an NDA to the FDA seeking to market sotagliflozin as a treatment for heart failure, kicking off the 60-day review period.